Good morning :)
Astal Laboratories Ltd

Astal Laboratories Ltd

ASTALLTD Share Price

BSE
₹63.242.56% (+1.58)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹276 cr, stock is ranked 2,463

Stock is 3.91x as volatile as Nifty

ASTALLTD Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

Avg

Can be considered moderately valued vs the market

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹276 cr, stock is ranked 2,463

Stock is 3.91x as volatile as Nifty

ASTALLTD Performance & Key Metrics

ASTALLTD Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
9.450.83—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
45.366.070.47%

ASTALLTD Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

ASTALLTD Company Profile

Astal Laboratories Ltd is engaged in the pharmaceutical bulk drug business, owning a manufacturing plant for pharmaceutical intermediates in Karnataka.

ASTALLTD Similar Stocks (Peers)

Compare with peers Compare with peers 

ASTALLTD Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.15
36.15
1Y Return
8.21%
8.21%
Buy Reco %
93.55
93.55
PE Ratio
80.71
80.71
1Y Return
22.06%
22.06%
Buy Reco %
85.19
85.19
LAURUSLABS
PE Ratio
147.36
147.36
1Y Return
143.12%
143.12%
Buy Reco %
61.54
61.54
PE Ratio
21.62
21.62
1Y Return
26.03%
26.03%
Buy Reco %
57.69
57.69
PE Ratio
27.42
27.42
1Y Return
11.75%
11.75%
Buy Reco %
67.74
67.74
Compare with Peers

ASTALLTD Forecast

ASTALLTD Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

ASTALLTD

ASTALLTD

Income

Balance Sheet

Cash Flow

ASTALLTD Income Statement

ASTALLTD Income Statement

Loading...

Quartermar 2025sep 2025dec 2025mar 2026jun 2026sep 2026
Total Revenue23.5037.5552.27134.15101.07108.20
Operating & Other expensessubtract19.2833.6548.68123.8688.6990.65
Depreciation/Amortizationsubtract0.100.120.120.860.860.88
Interest & Other Itemssubtract0.270.310.331.091.181.34
Taxes & Other Itemssubtract1.100.880.770.660.935.56
EPS2.802.402.192.042.192.23

ASTALLTD Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual report

PDF
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
 

ASTALLTD Stock Peers

ASTALLTD Past Performance & Peer Comparison

ASTALLTD Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Astal Laboratories Ltd18.790.83—
Sun Pharmaceutical Industries Limited36.155.380.85%
Torrent Pharmaceuticals Ltd80.7110.100.72%
Laurus Labs Ltd147.3624.110.08%
ScreenerCompare valuation on Screener

ASTALLTD Stock Price Comparison

Compare ASTALLTD with any stock or ETF
Compare ASTALLTD with any stock or ETF
ASTALLTD
Loading...

ASTALLTD Holdings

ASTALLTD Shareholdings

ASTALLTD Promoter Holdings Trend

ASTALLTD Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

ASTALLTD Institutional Holdings Trend

ASTALLTD Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

ASTALLTD Shareholding Pattern

ASTALLTD Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding4.59%0.00%0.00%0.00%95.41%

Mar 2026

May 2026

Jun 2026

Sep 2026

ASTALLTD Shareholding History

ASTALLTD Shareholding History

SepDec '25MarMayJunSep0.00%0.00%0.00%0.00%0.00%0.00%

ASTALLTD Insider Trades & Bulk Stock Deals

ASTALLTD Insider Trades & Bulk Stock Deals

Loading...

smallcases containing ASTALLTD stock

smallcases containing ASTALLTD stock

Looks like this stock is not in any smallcase yet.

ASTALLTD Events

ASTALLTD Events

ASTALLTD Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

ASTALLTD has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

ASTALLTD Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

ASTALLTD has not given any dividends in last 5 years

ASTALLTD Dividends

ASTALLTD Dividends

Hmm, looks like data is unavailable here. Please come back after some time

ASTALLTD Stock News & Opinions

ASTALLTD Stock News & Opinions

Earnings
Earnings
Astal Laboratories Ltd consolidated sales up 6.93% on year in Q2FY2027, net profit saw a mild growth of 3.72%

Astal Laboratories Ltd's net profit grew slightly 3.72% to Rs 9.77 crore, while revenue from operations slightly gained 6.93% to Rs 107.94 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, easing 6.94%. It has improved by 2.52% over last one week and ticked higher by 5.98% in last one month while the market capitalization of Astal Laboratories Ltd has marginally improved by 4.47% and 26.80% in the same period respectively. Profit before tax (PBT) of Astal Laboratories Ltd stood at Rs 15.33 crore in Q2 FY27, expanding by 341.79% year-on-year, and surging by 48.12% quarter-on-quarter. EBITDA came in at Rs 17 crore, rallying 343.49% YoY and jumping 40.63% sequentially. Total expenses posted a minor rise of 2.21% to Rs 91.53 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 86.46 crore, dropping by 13.64% YoY, while employee benefits expense was at Rs 2.76 crore, tumbling by 12.38% YoY. For FY26, revenue from operations jumped by 287.87% to Rs 249.13 crore, while net profit jumped 64.73% to Rs 14.71 crore, compared to previous FY. EBITDA surged by 1265% to Rs 20.55 crore, and PBT surged 48% to Rs 17.73 crore compared to previous FY. The company's consolidated net cash flow from operating activities stood at Rs 17.7 crore in FY26, as against Rs 12.52 crore in FY25. Astal Laboratories Ltd tumbled by 33.27% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.42% during the same period.

1 day agoCapital Market - Live
Earnings
Earnings
Astal Laboratories Ltd consolidated sales up 6.93% on year in Q2FY2027, net profit saw a mild growth of 3.72%

Astal Laboratories Ltd's net profit grew slightly 3.72% to Rs 9.77 crore, while revenue from operations improved marginally 6.93% to Rs 107.94 crore in Q2FY27 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 6.94%. It has improved by 2.52% over last one week and moved up slightly by 5.98% in last one month while the market capitalization of Astal Laboratories Ltd has inched up 4.47% and 26.80% in the same period respectively. Profit before tax (PBT) of Astal Laboratories Ltd stood at Rs 15.33 crore in Q2 FY27, surging by 341.79% year-on-year, and rallying 48.12% quarter-on-quarter. EBITDA came in at Rs 17 crore, expanding by 343.49% YoY and jumping 40.63% sequentially. Total expenses saw a slight increase of 2.21% to Rs 91.53 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 86.46 crore, dropping by 13.64% YoY, while employee benefits expense was at Rs 2.76 crore, tanking by 12.38% YoY. For FY26, revenue from operations witnessed a strong growth of 287.87% to Rs 249.13 crore, while net profit surged by 64.73% to Rs 14.71 crore, compared to previous FY. EBITDA soared by 1265% to Rs 20.55 crore, and PBT witnessed a strong rise of 48% to Rs 17.73 crore compared to previous FY. The company's consolidated net cash flow from operating activities stood at Rs 17.7 crore in FY26, as against Rs 12.52 crore in FY25. Astal Laboratories Ltd plunged by 33.27% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.42% during the same period.

1 day agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to convene board meeting November 13 to review financial results

Astal Laboratories Limited will hold a meeting of its Board of Directors on November 13, 2026, at its corporate office in Telangana to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with a Limited Review Report from the auditors. The company has closed the trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the board meeting's conclusion, in accordance with SEBI regulations.

1 week agoCapital Market - Live
Corporate
Corporate
Astal Laboratories confirms regulatory compliance for the quarter ended September 30, 2026

Astal Laboratories Limited submitted a certificate to the BSE Limited on October 14, 2026, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2026. The certificate, received from BEETAL FINANCIAL & COMPUTER SERVICES (P) LTD., the company's Registrar and Share Transfer Agent, verifies that securities received for dematerialization were confirmed to the depositories and that security certificates have been mutilated and cancelled.

1 month agoCapital Market - Live
Corporate
Corporate
Astal Laboratories closes securities trading window for insiders ahead of results release

Astal Laboratories Limited informed the BSE Limited that the trading window for dealing in securities of the company will be closed for all directors, officers, designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to convene board meeting in Telangana on September 4, 2026

Astal Laboratories Limited will hold a meeting of its Board of Directors on September 4, 2026, at its corporate office in Telangana to consider and approve the notice for the company’s 33rd Annual General Meeting, approve the Board Report for the financial year ended March 31, 2026, and appoint a scrutinizer for the AGM and remote e-voting.

2 months agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to convene board meeting August 14 to review quarterly financial results

Astal Laboratories Limited will hold a meeting of its Board of Directors on August 14, 2026, at its corporate office in Telangana to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with a Limited Review Report from the auditors.

3 months agoCapital Market - Live
Earnings
Earnings
Astal Laboratories consolidated net profit rises 180.29% in the March 2026 quarter

Net profit of Astal Laboratories rose 180.29% to Rs 7.68 crore in the quarter ended March 2026 as against Rs 2.74 crore during the previous quarter ended March 2025. Sales rose 471.15% to Rs 134.05 crore in the quarter ended March 2026 as against Rs 23.47 crore during the previous quarter ended March 2025. For the full year,net profit rose 64.73% to Rs 14.71 crore in the year ended March 2026 as against Rs 8.93 crore during the previous year ended March 2025. Sales rose 287.87% to Rs 249.13 crore in the year ended March 2026 as against Rs 64.23 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales134.0523.47 471 249.1364.23 288 OPM %7.6017.81 -8.3419.88 - PBDT9.203.95 133 18.9612.20 55 PBT8.343.85 117 17.7311.98 48 NP7.682.74 180 14.718.93 65 Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to convene board meeting

Astal Laboratories will hold a meeting of the Board of Directors of the Company on 30 May 2026.

5 months agoCapital Market - Live
Earnings
Earnings
Astal Laboratories standalone net profit declines 5.22% in the December 2025 quarter

Net profit of Astal Laboratories declined 5.22% to Rs 2.36 crore in the quarter ended December 2025 as against Rs 2.49 crore during the previous quarter ended December 2024. Sales rose 261.27% to Rs 52.24 crore in the quarter ended December 2025 as against Rs 14.46 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales52.2414.46 261 OPM %6.7822.96 - PBDT3.253.10 5 PBT3.133.02 4 NP2.362.49 -5 Powered by Capital Market - Live

8 months agoCapital Market - Live

Frequently asked questions

  1. The share price of ASTALLTD as on 13th November 2026 is ₹63.24. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Astal Laboratories Ltd (ASTALLTD) share are
    • Past 1 week: 4.77%
    • Past 1 month: -4.18%
    • Past 3 months: -28.53%
    • Past 6 months: -21.87%
    • Past 1 year: -33.27%
    • Past 3 years: 78.57%
    • Past 5 years: 696.59%

  3. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astal Laboratories Ltd (ASTALLTD) is ₹276.33 Cr as of 13th November 2026.

  4. The 52-week high of Astal Laboratories Ltd (ASTALLTD) is ₹98.74 and the 52-week low is ₹49.99.

  5. The P/E (price-to-earnings) ratio of Astal Laboratories Ltd (ASTALLTD) is 18.79. The P/B (price-to-book) ratio is 0.83.

  6. Astal Laboratories Ltd (ASTALLTD) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  7. You can directly buy Astal Laboratories Ltd (ASTALLTD) shares on Tickertape. Simply sign up, connect your demat account and place your order.